News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Markets saw minimal movement in the past hour with no major headlines to drive trading.
  • No significant economic data releases or central-bank statements were published during the hour.
  • No new geopolitical incidents or diplomatic developments emerged in the last hour.
  • There were no notable corporate announcements, earnings, mergers, or filings during the hour.
  • Commodity and currency prices held steady absent fresh catalysts in the past hour.
  • Trading volumes remained subdued without fresh headlines to spur activity.

Latest Articles

Immuneering Corporation Announces Grants of Inducement Awards

Immuneering Corporation Announces Grants of Inducement Awards

Immuneering Corporation announced the granting of inducement stock option awards to its newly appointed Chief Financial Officer, Andrew Gengos, and a non-executive employee. The options are part of the company's 2025 Employment Inducement Award Plan and are intended to incentivize service and align interests with shareholders. The company is focuse…

VALUE LINE, INC. DECLARES  A QUARTERLY CASH DIVIDEND OF $0.35 PER COMMON SHARE AND RENEWS STOCK REPURCHASE PROGRAM

VALUE LINE, INC. DECLARES A QUARTERLY CASH DIVIDEND OF $0.35 PER COMMON SHARE AND RENEWS STOCK REPURCHASE PROGRAM

Value Line, Inc. announced a quarterly cash dividend of $0.35 per share payable in August 2026 and approved a renewal of its stock repurchase program with up to $2 million authorized. The company emphasizes its confidence in its shares and continues to offer extensive investment research services to individual and institutional investors.

Hingham Reports Second Quarter 2026 Results

Hingham Reports Second Quarter 2026 Results

Hingham Institution for Savings reported strong second quarter 2026 results, with net income of $25.4 million, representing a 168.5% increase over the prior year quarter. Core net income also grew by 42.2%. The bank saw modest asset growth, strong deposit increases particularly in low-cost non-interest bearing deposits, and improved net interest ma…

Agencia Comercial Spirits Ltd Announces Entry into Construction, Network Infrastructure and Maintenance Agreements for Indonesia AI Computing Deployment

Agencia Comercial Spirits Ltd Announces Entry into Construction, Network Infrastructure and Maintenance Agreements for Indonesia AI Computing Deployment

Agencia Comercial Spirits Ltd, a Taiwan-based whisky importer and distributor listed on NASDAQ, announced that its subsidiaries have entered into contracts for the construction of a data center, procurement of network infrastructure, and a five-year technical support and maintenance agreement to support its planned AI computing infrastructure expan…

UFC Names Meridianbet Official Partner of Fight Night Belgrade

UFC Names Meridianbet Official Partner of Fight Night Belgrade

Meridian Holdings Inc.'s subsidiary Meridianbet has been named the official partner and exclusive sports-betting sponsor for UFC Fight Night Serbia, scheduled for August 1, 2026. This event marks the UFC's debut in Serbia and represents a major branding opportunity for Meridianbet, a leader in online sports betting with operations across Europe, Af…

Buy Merck Ahead of Lipfendra Milestone and Continued Oncology Rollouts

Buy Merck Ahead of Lipfendra Milestone and Continued Oncology Rollouts

Merck (MRK) is a Strong Buy on expectation of a near-term regulatory milestone for its new oncology candidate Lipfendra and continued commercialization of its oncology portfolio. The stock offers a compelling mix of steady cash generation (free cash flow $14.1B), a $315B market cap, and an established commercial engine. We lay out a clear entry, st…

Q2 Holdings: Oversold Fintech, Favorable Risk/Reward for a Long Rebound

Q2 Holdings: Oversold Fintech, Favorable Risk/Reward for a Long Rebound

<p>Q2 Holdings' share-price damage feels overstated relative to its fundamentals. The company has moved customers to the cloud, is producing positive free cash flow, and still grows revenue double digits — yet the stock trades nearer its 52-week low than its highs. This trade idea lays out a concrete long entry, stop and target with a clear 180-tra…

Micron: A Tactical Buy as Fundamentals Meet a Volatile Market

Micron: A Tactical Buy as Fundamentals Meet a Volatile Market

Micron’s pullback from its 52-week high has created a defined risk / reward for a mid-term swing. Strong profitability, massive free cash flow, and constrained supply for high-bandwidth memory underpin the bullish case, while sector-level volatility and bearish technicals argue for a disciplined entry, tight stop, and realistic target.

Roundtable Secures Enterprise Technology Platform Partnership with Mario Nawfal, the World’s #1 Most-Viewed Journalist

Roundtable Secures Enterprise Technology Platform Partnership with Mario Nawfal, the World’s #1 Most-Viewed Journalist

Roundtable (NASDAQ: RTB), an AI-powered and DeFi-enabled enterprise media platform, announced a comprehensive technology partnership with Mario Nawfal, the world's most-viewed journalist. Under this agreement, Roundtable will provide publishing, monetization, syndication, and business operation infrastructure for Nawfal's owned digital platform, ma…

ImmunityBio: Buy the Commercial Momentum Behind ANKTIVA Ahead of PDUFA

ImmunityBio: Buy the Commercial Momentum Behind ANKTIVA Ahead of PDUFA

ImmunityBio (IBRX) is a buy here. The market is discounting ANKTIVA's commercial momentum after an overreaction to promotional conduct headlines earlier this year. With an accepted sBLA, compelling QUILT efficacy numbers, and a PDUFA date of 01/06/2027, the path to re-rating is clear — but not risk-free. Trade plan: enter $7.70, stop $6.50, target …

CO2 Energy Transition Corp. (Nasdaq: NOEM) Signs Letter of Intent with Texas-Based Energy Company to Advance Domestic Lithium Recovery and Strontium Ferrite Production for Defense Applications

CO2 Energy Transition Corp. (Nasdaq: NOEM) Signs Letter of Intent with Texas-Based Energy Company to Advance Domestic Lithium Recovery and Strontium Ferrite Production for Defense Applications

CO2 Energy Transition Corp. (Nasdaq: NOEM), a special purpose acquisition company focused on energy transition, announced a non-binding Letter of Intent with a Texas-based oil and gas company to recover lithium and strontium from subsurface brines. This strategy seeks to leverage existing oilfield infrastructure to support domestic critical mineral…

Buying the Oral Wegovy Recovery: A Measured Long on Novo Nordisk

Buying the Oral Wegovy Recovery: A Measured Long on Novo Nordisk

Novo Nordisk has moved from broken market leadership to a credible comeback thanks to a successful oral Wegovy pill launch and improving technicals. At a $225.8B market cap and roughly 12x P/E, the stock looks like a recovery trade rather than a growth premium. This idea lays out an actionable long: entry at $50.59, stop at $45.00, target $68.00 ov…